Compare · BSX vs HTFL
BSX vs HTFL
Side-by-side comparison of Boston Scientific Corporation (BSX) and Heartflow Inc. (HTFL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and HTFL operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $70.88B, about 28.5x HTFL ($2.49B).
- Over the past year, BSX is down 53.7% and HTFL is down 3.5% - HTFL leads by 50.2 points.
- BSX has been more active in the news (21 items in the past 4 weeks vs 8 for HTFL).
- BSX has more recent analyst coverage (25 ratings vs 7 for HTFL).
- Company
- Boston Scientific Corporation
- Heartflow Inc.
- Price
- $47.70+0.02%
- $28.85-2.34%
- Market cap
- $70.88B
- $2.49B
- 1M return
- -16.10%
- -0.35%
- 1Y return
- -53.73%
- -3.51%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 21
- 8
- Recent ratings
- 25
- 7
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest HTFL
- Chief Medical Officer Rogers Campbell exercised 9,219 shares at a strike of $19.00 and sold $261,266 worth of shares (9,219 units at $28.34) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Heartflow Inc.
- SEC Form 10-Q filed by Heartflow Inc.
- Heartflow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Heartflow Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
- Chief Executive Officer Farquhar John C.M. sold $657,005 worth of shares (22,562 units at $29.12) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 519,397 units (SEC Form 4)
- A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech
- The Future of Intoxication Detection May Be in Your Voice
- Chief Accounting Officer Jones Marie L. covered exercise/tax liability with 567 units of Common Stock., decreasing direct ownership by 2% to 31,083 units (SEC Form 4) (withholding tax)
- Chief Medical Officer Rogers Campbell covered exercise/tax liability with 2,271 shares, decreasing direct ownership by 3% to 78,731 units (SEC Form 4) (withholding obligation)